Protein kinase CK2 Is a central regulator of topoisomerase i hyperphosphorylation and camptothecin sensitivity in cancer cell lines

Biochemistry

Volumn 50, Issue 5, 2011, Pages 704-714

  Bandyopadhyay, Keya ^a   Gjerset, Ruth A ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED RESISTANCE; ANTI-CANCER AGENTS; CAMPTOTHECINS; CANCER CELL LINES; CAUSE-AND-EFFECT RELATIONSHIPS; CELL LINES; CELLULAR FACTORS; CELLULAR RESPONSE; CELLULAR SENSITIVITY; CHEMOTHERAPEUTIC AGENTS; COMPLEX FORMATIONS; CYCLIN-DEPENDENT KINASE; HYPERPHOSPHORYLATION; IRINOTECAN; NORMAL TISSUE; PROTEIN KINASE C; PROTEIN KINASE CK2; SERINE KINASE; TOPOISOMERASE I; TOPOTECAN;

AMINO ACIDS; CELL CULTURE; CELLS; CHEMICAL ACTIVATION; DISEASES; ENZYMES; PHOSPHORYLATION; TUMORS;

BODY FLUIDS;

CAMPTOTHECIN; CASEIN KINASE II; CYCLIN DEPENDENT KINASE 1; DNA TOPOISOMERASE; PROTEIN KINASE C; PROTEIN SERINE KINASE;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CASEIN KINASE II; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; HUMANS; NEOPLASMS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY;

EID: 79952081873     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi101110e     Document Type: Article

References (87)

1. Champoux, J. J. (2001) DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413. (Pubitemid 32662215)
2. Wang, J. C. (2002) Cellular roles ofDNAtopoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol. 3, 430-440. (Pubitemid 34685700)
3. Pommier, Y. (2009) DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev. 109, 2894-2902.
4. Pfister, T. D., Reinhold, W. C., Agama, K., Gupta, S., Khin, S. A., Kinders, R. J., Parchment, R. E., Tomaszewski, J. E., Doroshow, J. H., and Pommier, Y. (2009) Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol. Cancer Ther. 8, 1878-1884.
5. Reinhold, W. C., Mergny, J. L., Liu, H., Ryan, M., Pfister, T. D., Kinders, R., Parchment, R., Doroshow, J., Weinstein, J. N., and Pommier, Y. (2010) Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res. 70, 2191-2203.
6. Bandyopadhyay, K., Lee, C., Haghighi, A., Baneres, J. L., Parello, J., and Gjerset, R. A. (2007) Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor. Biochemistry 46, 14325-14334. (Pubitemid 350250325)
7. Husain, I., Mohler, J. L., Seigler, H. F., and Besterman, J. M. (1994) Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54, 539-546. (Pubitemid 24053198)
8. Bronstein, I. B., Vorobyev, S., Timofeev, A., Jolles, C. J., Alder, S. L., and Holden, J. A. (1996) Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol. Res. 8, 17-25. (Pubitemid 26107683)
9. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T., and Tsuruo, T. (1990) Decreased expression of DNA topoisomerase I in camptothecin- resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50, 6925-6930. (Pubitemid 20361092)
10. Pommier, Y., Pourquier, P., Urasaki, Y., Wu, J., and Laco, G. S. (1999) Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Update 2, 307-318. (Pubitemid 30070455)
11. Dingemans, A. M., Pinedo, H. M., and Giaccone, G. (1998) Clinical resistance to topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400, 275-288. (Pubitemid 28475109)
12. Larsen, A. K., and Skladanowski, A. (1998) Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim. Biophys. Acta 1400, 257-274. (Pubitemid 28475108)
13. St-Amant, C., Lussier, S., Lehoux, J., Laberge, R. M., and Boissonneault, G. (2006) Altered phosphorylation of topoisomerase I following overexpression in an ovarian cancer cell line. Biochem. Cell Biol. 84, 55-66.
14. Coderoni, S., Paparelli, M., and Gianfranceschi, G. L. (1990) Role of calf thymus DNA-topoisomerase I phosphorylation on relaxation activity expression and on DNA-protein interaction. Role of DNAtopoisomerase I phosphorylation. Mol. Biol. Rep. 14, 35-39.
15. Durban, E., Mills, J. S., Roll, D., and Busch, H. (1983) Phosphorylation of purified Novikoff hepatoma topoisomerase I. Biochem. Biophys. Res. Commun. 111, 897-905. (Pubitemid 13081835)
16. Pommier, Y., Kerrigan, D., Hartman, K. D., and Glazer, R. I. (1990) Phosphorylation of mammalianDNAtopoisomerase I and activation by protein kinase C. J. Biol. Chem. 265, 9418-9422.
17. Samuels, D. S., Shimizu, Y., and Shimizu, N. (1989) Protein kinase C phosphorylates DNA topoisomerase I. FEBS Lett. 259, 57-60. (Pubitemid 20009945)
18. Cardellini, E., and Durban, E. (1993) Phosphorylation of human topoisomerase I by protein kinase C in vitro and in phorbol 12- myristate 13-acetate-activated HL-60 promyelocytic leukaemia cells. Biochem. J. 291 (Part 1), 303-307. (Pubitemid 23107786)
19. Durban, E., Goodenough, M., Mills, J., and Busch, H. (1985) Topoisomerase I phosphorylation in vitro and in rapidly growing Novikoff hepatoma cells. EMBO J. 4, 2921-2926.
20. Turman, M. A., and Douvas, A. (1993) A casein kinase type II (CKII)- like nuclear protein kinase associates with, phosphorylates, and activates topoisomerase I. Biochem. MED. Metab. Biol. 50, 210-225. (Pubitemid 23295788)
21. Yu, D., Khan, E., Khaleque, M. A., Lee, J., Laco, G., Kohlhagen, G., Kharbanda, S., Cheng, Y. C., Pommier, Y., and Bharti, A. (2004) Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity. J. Biol. Chem. 279, 51851-51861. (Pubitemid 39656552)
22. Hackbarth, J. S., Galvez-Peralta, M., Dai, N. T., Loegering, D. A., Peterson, K. L., Meng, X. W., Karnitz, L. M., and Kaufmann, S. H. (2008) Mitotic phosphorylation stimulatesDNArelaxation activity of human topoisomerase I. J. Biol. Chem. 283, 16711-16722.
23. Coderoni, S., Paparelli, M., and Gianfranceschi, G. L. (1990) Phosphorylation sites for typeNII protein kinase inDNA-topoisomerase I from calf thymus. Int. J. Biochem. 22, 737-746. (Pubitemid 20374326)
24. Kaiserman, H. B., Ingebritsen, T. S., and Benbow, R. M. (1988) Regulation of Xenopus laevis DNA topoisomerase I activity by phosphorylation in vitro. Biochemistry 27, 3216-3222.
25. Samuels, D. S., and Shimizu, N. (1992) DNA topoisomerase I phosphorylation in murine fibroblasts treated with 12-O-tetradecanoylphorbol-13- acetate and in vitro by protein kinase. J. Biol. Chem. 267, 11156-11162.
26. Staron, K., Kowalska-Loth, B., Nieznanski, K., and Szumiel, I. (1996) Phosphorylation of topoisomerase I in L5178Y-S cells is associated with poly(ADP-ribose) metabolism. Carcinogenesis 17, 383-387. (Pubitemid 26085314)
27. Staron, K., Kowalska-Loth, B., and Szumiel, I. (1996) Lowered phosphorylation of topoisomerase I is a direct reason for reduced sensitivity of L5178Y-S cells to camptothecin. Ann. N.Y. Acad. Sci. 803, 321-323. (Pubitemid 27058004)
28. Kowalska-Loth, B., Staron, K., Buraczewska, I., Szumiel, I., Kapiszewska, M., and Lange, C. S. (1993) Reduced sensitivity to camptothecin of topoisomerase I from a L5178Y mouse lymphoma subline sensitive to X-radiation. Biochim. Biophys. Acta 1172, 117-123. (Pubitemid 23065787)
29. Staron, K., Kowalska-Loth, B., and Szumiel, I. (1994) The sensitivity to camptothecin of DNA topoisomerase I in L5178Y-S lymphoma cells. Carcinogenesis 15, 2953-2955.
30. Staron, K., Kowalska-Loth, B., Zabek, J., Czerwinski, R. M., Nieznanski, K., and Szumiel, I. (1995) Topoisomerase I is differently phosphorylated in two sublines of L5178Y mouse lymphoma cells. Biochim. Biophys. Acta 1260, 35-42.
31. Ayrault, O., Karayan, L., Riou, J. F., Larsen, C. J., and Seite, P. (2003) Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I. Oncogene 22, 1945-1954.
32. Karayan, L., Riou, J. F., Seite, P., Migeon, J., Cantereau, A., and Larsen, C. J. (2001) Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 20, 836-848. (Pubitemid 32198177)
33. Chambers, A. F. (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 69, 5292-5293.
34. Reikhardt, B. A., Kulikova, O. G., Borisova, G. Y., Aleksandrova, I. Y., and Sapronov, N. S. (2003) Status of the "protein kinase CK2- HMG14" system in age-related amnesia in rats. Neurosci. Behav. Physiol. 33, 799-804. (Pubitemid 38129934)
35. Piotrovskii, L. B., and Dumpis, M. A. (1990) Selective alkylation of imidazole-4(5)-carboxamide. Chem. Heterocycl. Compd. 26, 407-409.
36. Yasuda, N. (1984) Synthesis of novel imidazole-4, 5-dicarboxamide derivatives. Synth. Commun. 14, 251-256.
37. Ruzzene, M., Penzo, D., and Pinna, L. A. (2002) Protein kinase CK2 inhibitor 4, 5, 6, 7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cellspecific protein 1 (HS1) in Jurkat cells. Biochem. J. 364, 41-47. (Pubitemid 34538944)
38. Soh, J. W., Lee, E. H., Prywes, R., and Weinstein, I. B. (1999) Novel roles of specific isoforms of protein kinase C in activation of the c-fos serum response element. Mol. Cell. Biol. 19, 1313-1324. (Pubitemid 29046873)
39. Saadatmandi, N., Tyler, T., Huang, Y., Haghighi, A., Frost, G., Borgstrom, P., and Gjerset, R. A. (2002) Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status. Cancer Gene Ther. 9, 830-839.
40. Ayrault, O., Andrique, L., Larsen, C. J., and Seite, P. (2004) Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes. Oncogene 23, 8097-8104. (Pubitemid 39531850)
41. Lee, C., Smith, B. A., Bandyopadhyay, K., and Gjerset, R. A. (2005) DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res. 65, 9834-9842. (Pubitemid 41541462)
42. Olnes, M. I., and Kurl, R. N. (1994) Isolation of nuclear extracts from fragile cells: a simplified procedure applied to thymocytes. BioTechniques 17, 828-829. (Pubitemid 24345991)
43. Furuta, T., Takemura, H., Liao, Z. Y., Aune, G. J., Redon, C., Sedelnikova, O. A., Pilch, D. R., Rogakou, E. P., Celeste, A., Chen, H. T., Nussenzweig, A., Aladjem, M. I., Bonner, W. M., and Pommier, Y. (2003) Phosphorylation of histone H2AXand activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNAdouble-strand breaks induced bymammalianDNAtopoisomerase I cleavage complexes. J. Biol. Chem. 278, 20303-20312. (Pubitemid 36799229)
44. Goldwasser, F., Bae, I., Valenti, M., Torres, K., and Pommier, Y. (1995) Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55, 2116-2121.
45. Zindy, F., Williams, R. T., Baudino, T. A., Rehg, J. E., Skapek, S. X., Cleveland, J. L., Roussel, M. F., and Sherr, C. J. (2003) Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 15930-15935. (Pubitemid 38021092)
46. Brenneisen, P., Wlaschek, M., Schwamborn, E., Schneider, L. A., Ma, W., Sies, H., and Scharffetter-Kochanek, K. (2002) Activation of protein kinase CK2 is an early step in the ultraviolet B-MEDiated increase in interstitial collagenase (matrix metalloproteinase-1; MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. Biochem. J. 365, 31-40. (Pubitemid 34756137)
47. Sarno, S., Reddy, H., Meggio, F., Ruzzene, M., Davies, S. P., Donella-Deana, A., Shugar, D., and Pinna, L. A. (2001) Selectivity of 4, 5, 6, 7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ("casein kinase-2"). FEBS Lett. 496, 44-48. (Pubitemid 32436419)
48. Marchand, C., Antony, S., Kohn, K. W., Cushman, M., Ioanoviciu, A., Staker, B. L., Burgin, A. B., Stewart, L., and Pommier, Y. (2006)A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol. Cancer Ther. 5, 287-295.
49. Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K. W., and Pommier, Y. (1991) Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 266, 20418-20423. (Pubitemid 21908475)
50. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. (1989) ProteinlinkedDNAstrand breaks induced inmammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49, 5016-5022. (Pubitemid 19239335)
51. Kjeldsen, E., Svejstrup, J. Q., Gromova II, Alsner, J., andWestergaard, O. (1992) Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J. Mol. Biol. 228, 1025-1030. (Pubitemid 23018485)
52. Koster, D. A., Palle, K., Bot, E. S., Bjornsti, M. A., and Dekker, N. H. (2007) Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 448, 213-217. (Pubitemid 47067371)
53. Porter, S. E., and Champoux, J. J. (1989) The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res. 17, 8521-8532. (Pubitemid 19273861)
54. Svejstrup, J. Q., Christiansen, K., Gromova II, Andersen, A. H., and Westergaard, O. (1991) New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. J. Mol. Biol. 222, 669-678.
55. Hsiang, Y. H., Lihou, M. G., and Liu, L. F. (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49, 5077-5082. (Pubitemid 19239347)
56. Tsao, Y. P., Russo, A., Nyamuswa, G., Silber, R., and Liu, L. F. (1993) Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 53, 5908-5914. (Pubitemid 24006159)
57. Rogakou, E. P., Boon, C., Redon, C., and Bonner, W. M. (1999) Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146, 905-916.
58. Liu, L. F., and Miller, K. G. (1981) EukaryoticDNAtopoisomerases: two forms of type IDNAtopoisomerases from HeLa cell nuclei. Proc. Natl. Acad. Sci. U.S.A. 78, 3487-3491. (Pubitemid 11059315)
59. Garcia, J. F., Villuendas, R., Sanchez-Beato, M., Sanchez-Aguilera, A., Sanchez, L., Prieto, I., and Piris, M. A. (2002) Nucleolar p14- (ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts. Am. J. Pathol. 160, 569-578. (Pubitemid 34160334)
60. Lee, Y. K., Park, J. Y., Kang, H. J., and Cho, H. C. (2003) Overexpression of p16INK4A and p14ARF in haematological malignancies. Clin. Lab. Haematol. 25, 233-237. (Pubitemid 36963184)
61. Sanchez-Aguilera, A., Sanchez-Beato, M., Garcia, J. F., Prieto, I., Pollan, M., and Piris, M. A. (2002) p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood 99, 1411-1418. (Pubitemid 34547099)
62. Sano, T., Masuda, N., Oyama, T., and Nakajima, T. (2002) Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol. Int. 52, 375-383. (Pubitemid 34748220)
63. Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., and Vousden, K. H. (1998) p14ARF links the tumour suppressors RB and p53. Nature 395, 124-125. (Pubitemid 28425642)
64. de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S. Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J., and Lowe, S. W. (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12, 2434-2442. (Pubitemid 28371362)
65. Palmero, I., Pantoja, C., and Serrano, M. (1998) p19ARF links the tumour suppressor p53 to Ras. Nature 395, 125-126. (Pubitemid 28425643)
66. Sherr, C. J. (2001) The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell. Biol. 2, 731-737. (Pubitemid 33679835)
67. Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424-2433. (Pubitemid 28371361)
68. Litchfield, D. W. (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1-15. (Pubitemid 36174119)
69. Seldin, D. C., and Leder, P. (1995) Casein kinase II alpha transgeneinduced murine lymphoma: relation to theileriosis in cattle. Science 267, 894-897.
70. Landesman-Bollag, E., Channavajhala, P. L., Cardiff, R. D., and Seldin, D. C. (1998) p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 16, 2965-2974. (Pubitemid 28297717)
71. Phan-Dinh-Tuy, F., Henry, J., Boucheix, C., Perrot, J. Y., Rosenfeld, C., and Kahn, A. (1985) Protein kinases in human leukemic cells. Am. J. Hematol. 19, 209-218. (Pubitemid 15033402)
72. Pena, J. M., Itarte, E., Domingo, A., and Cusso, R. (1983) Cyclic adenosine 3′:5′-monophosphate-dependent and -independent protein kinases in human leukemic cells. Cancer Res. 43, 1172-1175. (Pubitemid 13160040)
73. Munstermann, U., Fritz, G., Seitz, G., Lu, Y. P., Schneider, H. R., and Issinger, O. G. (1990) Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur. J. Biochem. 189, 251-257. (Pubitemid 20146007)
74. Daya-Makin, M., Sanghera, J. S., Mogentale, T. L., Lipp, M., Parchomchuk, J., Hogg, J. C., and Pelech, S. L. (1994) Activation of a tumor-associated protein kinase (p40TAK) and casein kinase 2 in human squamous cell carcinomas and adenocarcinomas of the lung. Cancer Res. 54, 2262-2268.
75. Faust, R. A., Gapany, M., Tristani, P., Davis, A., Adams, G. L., and AhMED, K. (1996) Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Cancer Lett. 101, 31-35. (Pubitemid 26060189)
76. Stalter, G., Siemer, S., Becht, E., Ziegler, M., Remberger, K., and Issinger, O. G. (1994) Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochem. Biophys. Res. Commun. 202, 141-147. (Pubitemid 24252576)
77. Kim, J. S., Eom, J. I., Cheong, J. W., Choi, A. J., Lee, J. K., Yang, W. I., and Min, Y. H. (2007) Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin. Cancer Res. 13, 1019-1028.
78. Hamacher, R., Saur, D., Fritsch, R., Reichert, M., Schmid, R. M., and Schneider, G. (2007) Casein kinase II inhibition induces apoptosis in pancreatic cancer cells. Oncol. Rep. 18, 695-701.
79. Izeradjene, K., Douglas, L., Delaney, A., and Houghton, J. A. (2005) Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 24, 2050-2058. (Pubitemid 40516198)
80. Trembley, J. H., Wang, G., Unger, G., Slaton, J., and AhMED, K. (2009) Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell. Mol. Life Sci. 66, 1858-1867.
81. Rothenberg, M. L. (2001) Irinotecan (CPT-11): recent developments and future directions;colorectal cancer and beyond. Oncologist 6, 66-80. (Pubitemid 32155817)
82. Pommier, Y. (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6, 789-802. (Pubitemid 44450467)
83. Rasheed, Z. A., and Rubin, E. H. (2003) Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22, 7296-7304. (Pubitemid 37487161)
84. Lanza, A., Tornaletti, S., Rodolfo, C., Scanavini, M. C., and Pedrini, A. M. (1996) Human DNA topoisomerase I-MEDiated cleavages stimulated by ultraviolet light-induced DNA damage. J. Biol. Chem. 271, 6978-6986. (Pubitemid 26104130)
85. Pourquier, P., Pilon, A. A., Kohlhagen, G., Mazumder, A., Sharma, A., and Pommier, Y. (1997) Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem. 272, 26441-26447. (Pubitemid 27458862)
86. Pourquier, P., Ueng, L. M., Kohlhagen, G., Mazumder, A., Gupta, M., Kohn, K. W., and Pommier, Y. (1997) Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J. Biol. Chem. 272, 7792-7796. (Pubitemid 27137335)
87. Bandyopadhyay, K., Baneres, J. L., Martin, A., Blonski, C., Parello, J., and Gjerset, R. A. (2009) Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiosensitization. Cell Cycle 8, 2779-2788.